Go Pro
OTCMKTS:NVLNF

Novelion Therapeutics (NVLNF) Stock Price, News & Analysis

$0.70 -0.01 (-1.20%)
As of 01/16/2020

About Novelion Therapeutics Stock (OTCMKTS:NVLNF)

Key Stats

Today's Range
$0.70
$0.75
50-Day Range
$0.70
$0.70
52-Week Range
$0.51
$1.00
Volume
26,900 shs
Average Volume
261,364 shs
Market Capitalization
$13.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive NVLNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVLNF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

NVLNF Stock Analysis - Frequently Asked Questions

Novelion Therapeutics' stock was trading at $0.7020 at the beginning of the year. Since then, NVLNF shares have increased by 0.0% and is now trading at $0.7020.

Top institutional shareholders of Novelion Therapeutics include BlackRock Inc. (8.50%), Sanctuary Advisors LLC (1.76%), Deutsche Bank AG (0.67%) and Corient Private Wealth LP (0.18%).
View institutional ownership trends
.

Shares of NVLNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:NVLNF
CIK
N/A
Fax
N/A
Employees
109
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$130.43 million
Price / Sales
0.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.69) per share
Price / Book
-0.15

Miscellaneous

Outstanding Shares
19,619,000
Free Float
N/A
Market Cap
$13.77 million
Optionable
Not Optionable
Beta
2.15
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:NVLNF) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners